VNA
VNDA icon

Valley National Advisers’s Vanda Pharmaceuticals VNDA Stock Holding History

Valley National Advisers’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09K Buy
342
+150
+78% +$980 ﹤0.01% 802
2026
Q1 		$1K Buy
+192
New +$1.48K ﹤0.01% 864

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Valley National Advisers's VNDA Position: Q2 2026 in Review

Valley National Advisers increased its Vanda Pharmaceuticals (VNDA) stake by 78% in Q2 2026, buying an estimated $980 and bringing the position to 342 shares worth $2.09K. The position accounts for ﹤0.01% of the portfolio, ranked #802.

Valley National Advisers first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Valley National Advisers held 342 shares of Vanda Pharmaceuticals worth $2.09K as of Q2 2026.
  • Valley National Advisers bought 150 Vanda Pharmaceuticals shares in Q2 2026, an estimated $980.
  • Vanda Pharmaceuticals made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #802 holding.
  • Valley National Advisers first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.